Loading…
Genomic diagnostics company making tests that help diagnose thyroid, lung, prostate and other cancers from tissue samples.
Genomic diagnostics company making tests that help diagnose thyroid, lung, prostate and other cancers from tissue samples.
Is paid per test: samples go to its own labs, which report a result, and Medicare and private insurers reimburse them, so coverage decisions matter as much as clinical results. The Afirma thyroid test has long been the base, with prostate and lung tests widening it.
Moat: narrow (IP / patents, data, regulatory licence). Proprietary genomic classifiers built on large clinical datasets are costly for rivals to replicate and validate.
Headquarters: South San Francisco, California · Founded: 2008 · Employees: 755
Size Veracyte (VCYT) is a United States Health Care company (Medical Specialties) with a market value of $1.94B, the 1814th largest of 3,117 United States companies the cockpit tracks. Shares closed at $24.16 on 6 Nov 2026.
Performance Over six months the shares fell 40.2%, against -4.2% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 17.3% over the last twelve months (peer median +11.6%); the operating margin is 17.2% (peer median 10.9%).
Valuation It trades at 14.9× forward earnings against a peer median of 38.8× (6th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -19 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.3 points below its cost of capital (14.6% WACC).
Short interest Short interest is 12.2% of the free float (15 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $562M | $517M | $446M | $361M | $297M |
| Revenue growth | — | +16% | +23% | +22% | — |
| Gross profit | $399M | $355M | $290M | $223M | $171M |
| EBITDA | $118M | $115M | $56.7M | $15.1M | -$8.36M |
| Net income | $114M | $66.4M | $24.1M | -$74.4M | -$36.6M |
| Free cash flow | $166M | $127M | $63.8M | $34.3M | -$1.01M |
| Capital expenditure | $12.4M | $9.68M | $11.3M | $9.96M | $8.55M |
| Total debt | $40.1M | $39.7M | $50.7M | $12.6M | $14.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Veracyte VCYT | $1.94B | -40% | +17% | 17% | 14.9× | 15.1% |
| Myriad Genetics MYGN | $566M | +38% | -3% | -11% | n/a | n/a |
| Natera NTRA | $44.8B | +60% | +38% | -11% | n/a | n/a |
| Guardant Health GH | $20.2B | +58% | +43% | -40% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VCYT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -44.6% | +0.3% | lowest of 21 |
| 6-month return | -40.2% | -4.2% | lowest of 21 |
| Distance from 52-week high | -60.3% | -28.8% | 2nd lowest of 21 |
| Revenue growth (TTM) | +17.3% | +11.6% | 10th highest of 21 |
| Operating margin | 17.2% | 10.9% | 6th highest of 21 |
| Forward P/E | 14.9× | 38.8× | 6th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 15.1% | 11.4% | 5th most demanding of 15 |
| Growth delivered (Del g) | +34.5% | +10.9% | 3rd highest of 15 |
| Hurdle (Req g minus delivered) | -19.4 pp | -7.8 pp | 3rd least demanding of 15 |
| ROIC minus cost of capital | -7.3 pp | +1.1 pp | 5th lowest of 21 |
| EV / EBITDA | 13.7× | 18.8× | 6th cheapest of 12 |
| Net debt / EBITDA | -3.8× | -0.9× | 3rd least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Veracyte VCYT | United States | $1.94B | -40% | +17% | 17% | 14.9× | 15.1% | +34.5% |
| Mehow Innovative 301363.SZ | China | $1.95B | -14% | +10% | 21% | 38.8× | 18.9% | +12.9% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.96B | -4% | +7% | 14% | 8.8× | -11.8% | +2.1% |
| SKAN SKAN.SW | Switzerland | $1.92B | +49% | +9% | 11% | 49.8× | 13.8% | +11.7% |
| JEOL 6951.T | Japan | $1.98B | -3% | -18% | 11% | 14.2× | 21.3% | +10.2% |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $1.89B | +17% | +5% | 7% | 9.4× | -12.6% | +0.4% |
| Establishment Labs ESTA | United States | $2.00B | -7% | +38% | -7% | n/a | n/a | n/a |
| DENTSPLY SIRONA XRAY | United States | $1.89B | -14% | -1% | 5% | 7.3× | 10.2% | +1.9% |
| Inspire Medical Systems INSP | United States | $1.85B | +45% | 0% | 2% | 45.4× | 30.9% | +51.2% |
| LeMaitre Vascular LMAT | United States | $1.85B | -25% | +12% | 29% | 26.2× | 2.9% | +14.0% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.85B | -5% | +11% | 25% | 53.2× | 6.6% | +14.6% |
| Medartis MED.SW | Switzerland | $1.83B | +47% | +30% | 2% | 74.2× | n/a | n/a |
| Wuxi Unicomp Technology 688531.SS | China | $1.80B | -36% | +53% | 12% | 40.7× | n/a | n/a |
| Fukuda Denshi 6960.T | Japan | $1.75B | -5% | 0% | 19% | 14.6× | -3.2% | -1.0% |
| Bonesupport BONEX.ST | Sweden | $2.16B | +34% | +25% | 25% | 61.9× | 13.3% | +45.4% |
| Embla Medical hf EMBLA.CO | Denmark | $1.75B | +3% | +6% | 14% | 17.9× | -1.8% | +8.3% |
| Angelalign Technology 6699.HK | Hong Kong | $1.74B | -7% | +84% | 9% | 52.1× | 18.1% | +25.8% |
| Poly Medicure POLYMED.NS | India | $1.73B | -4% | +18% | 17% | 40.6× | n/a | n/a |
| Kestra Medical Technologies KMTS | United States | $1.72B | +37% | +61% | -134% | n/a | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.71B | -5% | +33% | 10% | 26.9× | 12.5% | +7.4% |
| Butterfly Network BFLY | United States | $1.70B | +53% | +39% | -36% | n/a | n/a | n/a |